Breaking News

Evotec, Probiodrug in Alzheimer’s Assay Alliance

November 28, 2012

Will validate assays to support clinical trials

Evotec AG has entered into a collaboration with Probiodrug AG, a biopharmaceutical company focused on drug development for major age-related diseases. Evotec will set up and validate assays to support preclinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer’s disease (AD). Glutaminyl cyclase is a novel enzyme target discovered by Probiodrug, and plays a role in the pathogenesis of AD as well as potentially other diseases.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “We are pleased to enter this collaboration with Probiodrug to use our first class assay development capabilities to support the preclinical and clinical development of QC inhibitors in Alzheimer’s disease and other indications. This is a good example of how Evotec can support biotech companies with their specific drug discovery needs.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016